HK1231492A1 - 內化部分 - Google Patents
內化部分Info
- Publication number
- HK1231492A1 HK1231492A1 HK17105169.5A HK17105169A HK1231492A1 HK 1231492 A1 HK1231492 A1 HK 1231492A1 HK 17105169 A HK17105169 A HK 17105169A HK 1231492 A1 HK1231492 A1 HK 1231492A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- internalizing moieties
- internalizing
- moieties
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461926865P | 2014-01-13 | 2014-01-13 | |
US201461926863P | 2014-01-13 | 2014-01-13 | |
US201462042755P | 2014-08-27 | 2014-08-27 | |
US201462042771P | 2014-08-27 | 2014-08-27 | |
PCT/US2015/011269 WO2015106290A1 (en) | 2014-01-13 | 2015-01-13 | Internalizing moieties |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1231492A1 true HK1231492A1 (zh) | 2017-12-22 |
Family
ID=53524430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK17105169.5A HK1231492A1 (zh) | 2014-01-13 | 2017-05-22 | 內化部分 |
Country Status (7)
Country | Link |
---|---|
US (2) | US10221250B2 (zh) |
EP (2) | EP3711820A1 (zh) |
JP (2) | JP6709733B2 (zh) |
AU (1) | AU2015204446A1 (zh) |
CA (1) | CA2936102A1 (zh) |
HK (1) | HK1231492A1 (zh) |
WO (1) | WO2015106290A1 (zh) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6178785B2 (ja) | 2011-04-01 | 2017-08-09 | イェール ユニバーシティーYale University | 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用 |
WO2013138662A1 (en) | 2012-03-16 | 2013-09-19 | 4S3 Bioscience, Inc. | Antisense conjugates for decreasing expression of dmpk |
US10017581B2 (en) | 2013-02-20 | 2018-07-10 | Valerion Therapeutics, Llc | Methods and compositions for treatment of Pompe disease |
AU2015204446A1 (en) | 2014-01-13 | 2016-07-14 | Valerion Therapeutics, Llc | Internalizing moieties |
US10040867B2 (en) | 2014-03-04 | 2018-08-07 | Yale University | Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations |
US10238742B2 (en) | 2014-06-25 | 2019-03-26 | Yale University | Cell penetrating nucleolytic antibody based cancer therapy |
CA2995673A1 (en) * | 2014-08-27 | 2016-03-03 | Valerion Therapeutics, Llc | Internalizing moieties for treatment of cancer |
US11590242B2 (en) | 2016-06-15 | 2023-02-28 | Yale University | Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors |
US10781433B2 (en) | 2016-09-09 | 2020-09-22 | Valerion Therapeutics, Llc | Methods and compositions for treatment of Lafora disease |
CA3056703A1 (en) | 2017-03-20 | 2018-09-27 | Cancer Therapeutics Laboratories, Inc. | Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy |
US20200216568A1 (en) * | 2017-07-17 | 2020-07-09 | Nucleus Therapeutics Pty. Ltd. | Binding proteins 2 |
US20210137960A1 (en) | 2018-02-01 | 2021-05-13 | Yale University | Compositions and methods for inhibition of nuclear-penetrating antibodies |
EP3765062A4 (en) * | 2018-03-15 | 2022-04-13 | Valerion Therapeutics, LLC | METHODS AND COMPOSITIONS FOR THE TREATMENT OF POLYGLUCOUS DISORDERS |
BR112021003818A2 (pt) * | 2018-08-31 | 2021-05-25 | Yale University | composição, composição farmacêutica e método para modificar o genoma de uma célula |
US20210340279A1 (en) | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
SG11202101984PA (en) * | 2018-08-31 | 2021-03-30 | Univ Yale | Compositions and methods for enhancing triplex and nuclease-based gene editing |
EP4021496A1 (en) * | 2019-08-30 | 2022-07-06 | Yale University | Compositions and methods for delivery of nucleic acids to cells |
WO2021077070A1 (en) | 2019-10-18 | 2021-04-22 | Yale University | Compositions and methods for inhibition of cell-penetrating antibodies |
US20230265214A1 (en) | 2020-08-31 | 2023-08-24 | Yale University | Compositions and methods for delivery of nucleic acids to cells |
CN117295753A (zh) | 2020-12-04 | 2023-12-26 | 基那奥生物公司 | 用于将核酸递送到细胞的组合物和方法 |
CA3212421A1 (en) | 2021-03-03 | 2022-09-09 | Yale University | Compositions and methods for treating skeletal muscle disease |
WO2023278897A1 (en) | 2021-07-02 | 2023-01-05 | Yale University | Compositions and methods for treating cancers |
AU2022340804A1 (en) | 2021-08-31 | 2024-03-21 | Gennao Bio, Inc. | Compositions and methods for treating cancers |
WO2023168352A1 (en) * | 2022-03-03 | 2023-09-07 | Yale University | Humanized 3e10 antibodies, variants, and antigen binding fragments thereof |
WO2023168401A1 (en) | 2022-03-03 | 2023-09-07 | Yale University | Compositions and methods for treating disease |
WO2023168427A1 (en) | 2022-03-03 | 2023-09-07 | Yale University | Compositions and methods for delivering therapeutic polynucleotides for exon skipping |
WO2024055034A1 (en) | 2022-09-09 | 2024-03-14 | Yale University | Proteolysis targeting antibodies and methods of use thereof |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
JP2000507225A (ja) * | 1996-03-08 | 2000-06-13 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | mab 3E10 ならびにその突然変異体および/または機能性フラグメントを使用する送達システム |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
US20100143358A1 (en) | 2007-01-22 | 2010-06-10 | The United States Government As Represented By The Department Of Veterans Affairs | Use of Antibody Conjugates |
AU2008256644B2 (en) | 2007-05-24 | 2014-07-03 | The United States Government As Represented By The Department Of Veterans Affairs | Intranuclear protein transduction through a nucleoside salvage pathway |
US8609615B2 (en) | 2008-10-15 | 2013-12-17 | Valerion Therapeutics, Llc | Methods and compositions for treatment of myotonic dystrophy |
BRPI1011236A2 (pt) * | 2009-06-15 | 2019-07-09 | 4S3 Bioscience Inc | métodos e composições para tratamento de miopatia miotubular usando polipeptídeos quiméricos compreendendo polipeptídeos miotubularesih 1 (mtm1) |
GB2476671B (en) | 2010-01-04 | 2014-11-26 | Plastic Logic Ltd | Touch-sensing systems |
JP5240316B2 (ja) | 2010-10-26 | 2013-07-17 | 株式会社デンソー | 車両乗員非操作運転システム |
WO2012145125A1 (en) | 2011-03-25 | 2012-10-26 | 4S3 Bioscience Inc. | Targeted radionuclides |
JP6178785B2 (ja) * | 2011-04-01 | 2017-08-09 | イェール ユニバーシティーYale University | 細胞浸透性抗dna抗体およびdna修復を阻害するためのその使用 |
JP2014510188A (ja) | 2011-04-05 | 2014-04-24 | シェブロン・オロナイト・カンパニー・エルエルシー | 低粘度舶用シリンダ潤滑油組成物 |
WO2013138662A1 (en) | 2012-03-16 | 2013-09-19 | 4S3 Bioscience, Inc. | Antisense conjugates for decreasing expression of dmpk |
US9283272B2 (en) | 2012-03-30 | 2016-03-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
WO2013177428A1 (en) | 2012-05-23 | 2013-11-28 | Valerion Therapeutics, Inc. | Methods for increasing muscle contractility |
WO2014130722A1 (en) | 2013-02-20 | 2014-08-28 | Valerion Therapeutics, Llc | Methods and compositions for treatment of forbes-cori disease |
US10017581B2 (en) | 2013-02-20 | 2018-07-10 | Valerion Therapeutics, Llc | Methods and compositions for treatment of Pompe disease |
AU2015204446A1 (en) | 2014-01-13 | 2016-07-14 | Valerion Therapeutics, Llc | Internalizing moieties |
US10202591B2 (en) | 2014-06-13 | 2019-02-12 | Valerion Therapeutics, Llc | Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders |
CA2995673A1 (en) | 2014-08-27 | 2016-03-03 | Valerion Therapeutics, Llc | Internalizing moieties for treatment of cancer |
-
2015
- 2015-01-13 AU AU2015204446A patent/AU2015204446A1/en not_active Abandoned
- 2015-01-13 EP EP20169442.9A patent/EP3711820A1/en not_active Withdrawn
- 2015-01-13 WO PCT/US2015/011269 patent/WO2015106290A1/en active Application Filing
- 2015-01-13 EP EP15735467.1A patent/EP3094646B1/en active Active
- 2015-01-13 CA CA2936102A patent/CA2936102A1/en not_active Abandoned
- 2015-01-13 US US15/111,160 patent/US10221250B2/en active Active
- 2015-01-13 JP JP2016545971A patent/JP6709733B2/ja not_active Expired - Fee Related
-
2017
- 2017-05-22 HK HK17105169.5A patent/HK1231492A1/zh unknown
-
2019
- 2019-03-04 US US16/291,896 patent/US10703824B2/en active Active
-
2020
- 2020-02-25 JP JP2020029459A patent/JP2020096636A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2015106290A1 (en) | 2015-07-16 |
EP3094646A1 (en) | 2016-11-23 |
AU2015204446A1 (en) | 2016-07-14 |
US10703824B2 (en) | 2020-07-07 |
JP2020096636A (ja) | 2020-06-25 |
US10221250B2 (en) | 2019-03-05 |
EP3711820A1 (en) | 2020-09-23 |
EP3094646A4 (en) | 2017-07-05 |
JP2017503511A (ja) | 2017-02-02 |
CA2936102A1 (en) | 2015-07-16 |
EP3094646B1 (en) | 2020-04-15 |
US20170174790A1 (en) | 2017-06-22 |
JP6709733B2 (ja) | 2020-06-17 |
US20190292276A1 (en) | 2019-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1231492A1 (zh) | 內化部分 | |
DK3237446T3 (en) | Anti-PD-1-antistoffer | |
DK3236972T3 (en) | Antivirale N4-hydroxycytidin-derivativer | |
DK3373003T3 (en) | Urinteststrimmel | |
ZA201704297B (en) | Pyrrolobenzodiazepine-antibody conjugates | |
AU361515S (en) | Dishrack | |
HUE055424T2 (hu) | Antitest-fynomer konjugátumok | |
AU362944S (en) | Lapboard | |
GB2533294B (en) | Micro-hotplates | |
DK3191586T3 (en) | Cellobiosephosphorylase | |
DK3178931T3 (en) | Anti-orai1-antistof | |
DK3002465T3 (en) | Hydrauliksystem | |
DK3234061T3 (en) | Nano-inhibitorer | |
DK3194944T3 (en) | Tomografiapparat | |
DK3145380T3 (en) | Toiletventilationssystem | |
AU5585P (en) | Lanutah Mandevilla sanderi | |
AU5598P (en) | Lanidaho Mandevilla sanderi | |
AU5594P (en) | Lanoregon Mandevilla sanderi | |
AU5593P (en) | Lanmissouri Mandevilla sanderi | |
AU5597P (en) | Lancalifornia Mandevilla sanderi | |
AU5596P (en) | Lannevada Mandevilla sanderi | |
AU5591P (en) | Lanmontana Mandevilla sanderi | |
AU5583P (en) | Lanminnesota Mandevilla sanderi | |
AU5584P (en) | Laniowa Mandevilla sanderi | |
AU5288P (en) | FLOMANTOG Mandevilla sanderi |